Design, synthesis, and biological evaluation of novel somatostatin receptor subtype-2 agonists: Optimization for potency and risk mitigation of hERG a...
Basic Information
ID: ALA4840347
Journal: Bioorg Med Chem
Title: Design, synthesis, and biological evaluation of novel somatostatin receptor subtype-2 agonists: Optimization for potency and risk mitigation of hERG and phospholipidosis.
Authors: Ishida A, Okabe Y, Matsushita T, Sekiguchi T, Nishio T, Komagata T, Iwaki M, Miyata H, Katagi J, Naganawa A, Maruyama T, Imagawa A.
Abstract: Somatostatin receptors are members of G-protein coupled receptor superfamily. Receptors can be classified into five subtypes, SSTR1 to 5. The highly potent and orally active SSTR2 agonist 7, which had been identified by our group, was found out to have toxicological liabilities such as hERG inhibition and phospholipidosis (PLD). We investigated the relationship between in silico physicochemical properties and hERG and PLD, and explored well-balanced agonists to identify amide 19 and benzimidazole 30. As a result of this exploration, we found out that the value of (cLogP) [2] + (pKa) [2] needs to be less than 110 to mitigate the liabilities.
CiteXplore: 34626901
DOI: 10.1016/j.bmc.2021.116424
Patent ID: ┄